VistaGen Therapeutics (VTGN) Reports PALISADE-1 Phase 3 Study Did not Meet Primary Endpoint - StreetInsider.com

Submitted by Anonymous (not verified) on Fri, 07/22/2022 - 12:03

VistaGen Therapeutics (VTGN) Reports PALISADE-1 Phase 3 Study Did not Meet Primary Endpoint  StreetInsider.com